Truist raised the firm’s price target on Merck to $139 from $122 and keeps a Buy rating on the shares. The company reported a Q4 earnings beat and the management expects continued growth from Keytruda, particularly in early lung cancer, ADCs, and anticipates a strong sotatercept launch in PAH, the analyst tells investors in a research note. The firm adds that it is positive on Merck’s robust cash generation, solid dividend yield, and management focus on shareholder return.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Merck & Company Launches 2024 Global Restructuring Program
- Merck (NYSE:MRK) Delivers Better-than-Expected Results in Q4
- Options Volatility and Implied Earnings Moves Today, February 01, 2024
- Merck reports Q4 Keytruda sales $6.6B, up 21% y/y
- Merck says Harpoon acquisition included in FY24 guidance
Questions or Comments about the article? Write to editor@tipranks.com